All In Biotech

Drug Trial Radar · NCT00403793

Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)

A Phase II -b, Placebo-Controlled Trial Investigating the Efficacy, Safety and Pharmacokinetics of a Subcutaneous Etonogestrel Implant Combined With i.m. Testosterone Undecanoate for Male Contraception

Last checked: Nov 19, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Oct 2003

Primary completion

Dec 2006

Study completion Dec 2006

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
Collaborators
Bayer
First posted
Nov 27, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.

Conditions

  • Contraception

Interventions

  • etonogestrel with testosterone undecanoateDrug

    42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks

  • PlaceboDrug

    42 or 44 weeks with placebo implant and placebo injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. % of men who had a sperm concentration of 1 million/ml or less at week 16.Time frame: Week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.